SINGAPORE-- Harbin Gloria Pharmaceuticals will pay RMB 2.39 billion to acquire an 85% stake in Shanxi Powerdone Pharmaceutics, one of two domestic deals in late January involving mainland firms reshuffling biotech assets and traditional Chinese medicines.
SINGAPORE-- Despite missing its target for bringing 15 to 20 drugs to the U.S. market last year, Lupin is optimistic enough about 2015 that it seeks possible acquisitions in Russia to expand its presence there.
The U.S. FDA is hiring new inspectors in India to tackle the high rate of marketing applications made by local firms, an agency official said.
SINGAPORE-- Sometimes it must seem to Pakistan's health authorities they can do nothing right in regulating the nation's pharmaceutical industry.
With recent news of clinical trials for its low-cost HPV vaccine, the Serum Institute has already made waves in the world of Big Pharma. The India-based vaccinemaker is now gearing up to challenge the world's leading vaccinemakers in another area: pertussis.
India's health ministry reportedly is drafting a requirement that pharmaceuticals carry barcodes at the primary level of packaging.
MicroConstants China has signed a licensing agreement to gain the global rights for the development of AA98 antibody drug candidates from the Institute of Biophysics of the Chinese Academy of Sciences in a unique deal between academia and local industry.
When the just-ended New York negotiations failed to resolve drug-patenting and other intellectual property issues, the focus shifted to a ministerial-level meeting of the Trans-Pacific Partnership expected to take place in March.
SINGAPORE-- India's government is getting into the generic drug business. The state reportedly will launch its own brand, "Jan Aushadhi," on July 1, planning to sell up to 504 drugs on its "essential" list in direct competition with commercial drugmakers.
France's Sanofi has taken dramatic steps to increase its diabetes-related presence in India with shades of Viehbacher plans.